Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IOngoingNov 29, 2023LEADER brand Lubricant Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0133-2024Class IOngoingNov 29, 2023LEADER brand Dry Eye ReliefNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0132-2024Class IOngoingNov 29, 2023LEADER brand Eye Irritation ReliefNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0131-2024Class IOngoingNov 29, 2023ELCYS (cysteine hydrochloride injection)Presence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0118-2024Class IOngoingNov 29, 2023Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mLPresence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0117-2024Class IOngoingNov 29, 20238.4% Sodium Bicarbonate InjectionPresence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0116-2024Class IITerminatedNov 29, 2023TiglutikFailed Viscosity Specifications: Out-of-specification test results for viscosityItf Pharma Inc · D-0115-2024Class IIITerminatedNov 29, 2023Lisinopril Tablets USP 20 mgPresence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lotsNCS Healthcare of Kentucky Inc · D-0114-2024Class IIITerminatedNov 29, 2023Buspirone Hydrochloride Tabs USP 10 mgPresence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lotsNCS Healthcare of Kentucky Inc · D-0113-2024Class IIITerminatedNov 29, 2023Esomeprazole Magnesium Delayed-Release CapsulesFailed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in...Glenmark Pharmaceuticals Inc., USA · D-0112-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC 70-VACGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0111-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC70-LVCGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0110-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC 70-LMCGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0109-2024Class ITerminatedNov 29, 2023Lubricating Tears Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0108-2024Class ITerminatedNov 29, 2023Polyvinyl Alcohol 1.4% Lubricating Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0107-2024Class IITerminatedNov 22, 2023Oxygen, Compressed USPcGMP DeviationsFamily Medical Supply Inc · D-0106-2024Class IIOngoingNov 22, 2023Equate Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0105-2024Class IIOngoingNov 22, 2023DOP Instant Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0104-2024Class IIOngoingNov 22, 2023DOP Instant Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0103-2024Class ITerminatedNov 15, 20232% Lidocaine HCl InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0102-2024Class ITerminatedNov 15, 20231% Lidocaine HCl InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0101-2024Class ITerminatedNov 15, 20234.2% Sodium Bicarbonate InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0100-2024Class IIITerminatedNov 15, 2023V-FORCE HomeopathicIncorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product...Grato Holdings, Inc. · D-0099-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0098-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0097-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0096-2024Class IIOngoingNov 15, 2023Deferasirox Tablets for Oral SuspensionFailed Dissolution SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0095-2024Class IIIOngoingNov 15, 2023Oxaydo (oxycodone HClSub-potent Drug: Lower potency than labeled.Zyla Life Sciences US Inc. · D-0094-2024Class IIITerminatedNov 15, 2023Mycophenolate Mofetil for Oral SuspensionDefective Container: The adaptor does not fit into the neck of the bottle after reconstitution with water.VistaPharm LLC · D-0093-2024Class IIOngoingNov 15, 2023Ranolazine Extended-Release Tablets 500mgFailed Dissolution Specifications: Out of specification for dissolution.Glenmark Pharmaceuticals Inc., USA · D-0092-2024Class IITerminatedNov 15, 2023Clinical TREAT Antifungal PowderCGMP deviations: the product was shipped from the Manufacturer to a Medline warehouse and released to stock while it was still under investigation for low assay results...MEDLINE INDUSTRIES, LP - Northfield · D-0091-2024Class IITerminatedNov 15, 2023Extended Phenytoin Sodium CapsulesFailed Dissolution SpecificationsAmneal Pharmaceuticals of New York, LLC · D-0090-2024Class IIITerminatedNov 15, 2023Hydrocortisone 1% and Acetic Acid 2% Otic Solution USPFailed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the...Taro Pharmaceuticals Inc. · D-0089-2024Class IIIOngoingNov 15, 2023SynthroidLabeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg...AbbVie Inc. · D-0088-2024Class IITerminatedNov 15, 2023Buprenorphine HClCrystallization; identified as Buprenorphine free basePAR Sterile Products LLC · D-0087-2024Class IITerminatedNov 15, 2023Montelukast Sodium TabletsPresence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.Dr. Reddy's Laboratories, Inc. · D-0086-2024Class IIITerminatedNov 8, 2023Bisoprolol Fumarate and Hydrochlorothiazide TabletsFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0085-2024Class IITerminatedNov 8, 2023Liothyronine Sodium TabletsFailed Impurities/Degradation Specifications.Sun Pharmaceutical Industries Inc · D-0084-2024Class IITerminatedNov 8, 2023Liothyronine Sodium TabletsFailed Impurities/Degradation Specifications.Sun Pharmaceutical Industries Inc · D-0083-2024Class IITerminatedNov 8, 2023Strong Iodine Solution U.S.PCGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.Safecor Health, LLC · D-0082-2024

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.